Floatz logo

URACIL RIBOSIDE

Nutrition Disorders

National Institute of Allergy and Infectious Diseases (NIAID)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Nutrition Disorders cohort.

Asset / SponsorPhaseRating
METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA
Taipei Veterans General Hospital, Taiwan
Phase 4BB
Intralipid
Johane Allard
Phase 4BB
ZIDOVUDINE
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Phase 4BB
Guanfacine
Maimonides Medical Center
Phase 4BB
Lamivudine
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Phase 4BB

View all 33 →

Same molecule, other indications

URACIL RIBOSIDE is also rated in:

lipodystrophyDormant
BB
Indicative ·
70 / 100
View asset →
HIV infectious diseaseDormant
BB
Indicative ·
69 / 100
View asset →
metabolic diseaseDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →